Fungal Infections Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in Fungal Infections therapeutics.
Synopsis
- In 2022, there will be more than three million incident cases of fungal Infections across 16 pharmaceutical markets.
- There are several marketed innovator drugs for the treatment of fungal infections, mostly cytochrome P450 and beta glucan synthase enzyme inhibitors.
- The fungal infections pipeline is strong with three products in pre-registration and seven products in Phase III development.
- Commercial sponsors dominate clinical trial development in fungal infections, with the US emerging as the key countries for conducting Phase III trials in fungal infections.
- Acquisition was the most common deal type in Europe and Asia, accounting for over 35% deals.
GlobalData’s Fungal Infections Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Fungal Infections market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Fungal Infections market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Key Findings
- Disease Overview
- Epidemiology Overview
- Epidemiology Overview: Incident Cases of FI in 2022
- Treatment Overview
- Treatment Guidelines
- Marketed Drugs Assessment
- Marketed Drugs – Leading Marketed Drugs in FI
- Marketed Drugs – Overview by Mechanism of Action
- Marketed Drugs – Overview by Route of Administration
- Marketed Drug Profile: Pfizer's Vfend
- Marketed Drug Profile: Merck's Noxafil
- Marketed Drug Profile: Basilea's Cresemba
- Marketed Drug Profile: Mycovia's Vivjoa
- Marketed Drug Profile: Merck's Cancidas
- Marketed Drug Profile: Astellas's Funguard/Mikamin/Mycamine
- Marketed Drug Profile: Mayne's Traisdin; Lozanoc; Tolsura
- Marketed Drug Profile: Scynexis's Brexafemme
- Marketed Drug Profile: Horizon's Rayos
- Pricing and Reimbursement Assessment
- Marketed Products – Manufacturer Price (in $/mg) for Infusion Formulations
- Marketed Products – Manufacturer Price (in $/mg) for Oral Formulations
- Marketed Products – Manufacturer Price (in $/mg)
- Marketed Products – Time to Pricing and Reimbursement for Isavuconazole
- Marketed Products – Time to Pricing and Reimbursement for SUBA-Itraconazole
- Marketed Products – Time to Pricing and Reimbursement for Posaconazole
- Pipeline Drugs Assessment
- Pipeline Drugs Overview – Pre-registration and Phase III Pipeline Drugs in FI# (1/2)
- Pipeline Drugs – Overview by Development Stage
- Pipeline Drugs – Overview by Mechanism of Action
- Pipeline Drugs – Overview by Route of Administration
- Pipeline Drugs – Overview by Molecule Type
- Pipeline Drugs – Phase Transition Success Rates and Likelihood of Approval in FI
- Pipeline Drugs – Drug-Specific Phase Transition Success Rate and Likelihood of Approval in FI (1/3)
- Clinical Trials Assessment
- Clinical Trials in FI – Historical Overview
- Clinical Trials in FI – Overview by Phase
- Clinical Trials in FI – Overview by Status
- Clinical Trials in FI – Overview by Phase for Ongoing and Planned Trials
- Clinical Trials in FI – Trials with a Virtual Component
- Clinical Trials in FI – Geographic Overview
- Clinical Trials in FI – Single-Country and Multinational Trials by Region
- Clinical Trials in FI – Top 20 Sponsors with Breakdown by Phase
- Clinical Trials in FI – Top 20 Sponsors with Breakdown by Status
- Clinical Trials in FI – Overview by Endpoint Status
- Clinical Trials in FI – Overview by Race and Ethnicity
- Clinical Trials in FI – Enrollment Data
- Table Enrollment data for Phase II trials in FI
- Table Enrollment data for Phase III trials in FI
- Clinical Trials in FI – Overview of Sites by Geography
- Clinical Trials in FI – Top 20 Countries for Trial Sites
- Clinical Trials in FI – Top 20 Sites Globally
- Clinical Trials – Feasibility Analysis: Geography Overview
- Table The top countries where GlobalData recommends running a Phase III trial in FI include the US, India, Germany, France, and Spain, among others.
- Clinical Trials – Feasibility Analysis: Benchmark Models for FI
- Deals Landscape
- Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in FI by Region
- Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in FI
- Commercial Assessment
- Commercial Assessment – Key Market Players in FI
- Future Market Catalysts
- Future Market Catalysts – Upcoming Market Catalysts in FI
- Appendix
- Methodology
- Methodology – Sales Forecasts
- Methodology – Pricing and Reimbursement
- Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis
- About the Authors
- Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook